AGO1

Across TCGA pan-cancer cohorts, AGO1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AGO1 data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher AGO1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AGO1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

UCEC, CCRCC, and PDAC are the cancer types where AGO1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.467	0.946	.002	40	view →
CCRCC	OS	Median	III,IV	0.950	0.640	.003	34	view →
PDAC	OS	Median	II,III,IV	0.753	0.956	.016	4	view →
LUAD	DFS	Quartile	II,III,IV	0.613	0.967	.025	4	view →
HNSC	OS	Median	IV	0.636	0.824	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AGO1–UCEC (DFS)

Open the UCEC breakdown →